Baxter International Inc (NYSE:BAX) SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total value of $1,918,947.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Baxter International Inc (NYSE BAX) opened at $68.41 on Friday. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. Baxter International Inc has a 12-month low of $44.56 and a 12-month high of $68.86. The company has a market capitalization of $37,270.00, a price-to-earnings ratio of 36.98, a P/E/G ratio of 2.01 and a beta of 0.69.
Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, beating the consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The company had revenue of $2.71 billion for the quarter, compared to analysts’ expectations of $2.66 billion. During the same period last year, the firm posted $0.56 earnings per share. Baxter International’s revenue was up 5.8% compared to the same quarter last year. research analysts predict that Baxter International Inc will post 2.43 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. Stillwater Investment Management LLC boosted its position in shares of Baxter International by 271.9% during the fourth quarter. Stillwater Investment Management LLC now owns 75,133 shares of the medical instruments supplier’s stock valued at $3,816,000 after buying an additional 54,928 shares during the last quarter. Atlantic Trust Group LLC boosted its position in shares of Baxter International by 120.6% during the third quarter. Atlantic Trust Group LLC now owns 58,108 shares of the medical instruments supplier’s stock valued at $3,645,000 after buying an additional 31,763 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in shares of Baxter International during the third quarter valued at $9,871,000. Parametric Portfolio Associates LLC boosted its position in shares of Baxter International by 4.6% during the third quarter. Parametric Portfolio Associates LLC now owns 1,666,746 shares of the medical instruments supplier’s stock valued at $104,588,000 after buying an additional 73,771 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of Baxter International during the third quarter valued at $175,000. 83.78% of the stock is currently owned by institutional investors.
BAX has been the topic of a number of recent research reports. Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Morgan Stanley increased their target price on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 26th. Bank of America reissued a “hold” rating on shares of Baxter International in a research note on Wednesday, November 22nd. Barclays increased their target price on Baxter International from $70.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, October 26th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $70.00 target price on shares of Baxter International in a research note on Friday, October 13th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $68.64.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.